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Abstract
Purpose of review—Pediatric cardiomyopathy is a rare disease with a genetic basis. The 
purpose of this review is to discuss the current status of genetic findings in the pediatric 
cardiomyopathy population and present recent progress in utilizing this information for 
management and therapy.
Recent findings—With increased clinical genetic testing, an understanding of the genetic 
causes of cardiomyopathy is improving and novel causes are identified. Recent progress in 
identifying the scope of genetic variation in large population datasets has led to reassessment and 
refinement of our understanding of the significance of rare genetic variation. As a result, the 
stringency of variant interpretation has increased, at times leading to revision of previous mutation 
results. Transcriptome and epigenome studies are elucidating important pathways for disease 
progression and highlight similarities and differences from adult cardiomyopathy. Therapy 
targeted toward the underlying cause of cardiomyopathy is emerging for a number of rare 
syndromes such as Pompe and Noonan syndromes, and genome editing and induced pluripotent 
stem cells provide promise for additional precision medicine approaches.
Summary—Genetics is moving at a rapid pace in pediatric cardiomyopathy. Genetic testing is 
increasingly being incorporated into clinical care. While challenges in interpretation of rare 
genetic variation remains challenging, the opportunity to provide management and therapy 
targeted toward the underlying genetic cause is beginning to be realized.
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Introduction
Cardiomyopathy is a rare disease in the pediatric population, estimated to affect 1 in 100,000 
individuals.(1, 2) The causes of cardiomyopathy are diverse and include infectious, 
environmental, and genetic causes. Since the original identification of mutations in MYH7, a 
gene encoding the thick filament ATPase β myosin heavy chain, as causative of hypertrophic 
cardiomyopathy (HCM) 25 years ago, there has been ongoing discovery of genes that cause 
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this disease. The speed of discovery has been enhanced by improved sequencing 
technologies that allow rapid, efficient, and cost effective testing. As a result, the array of 
clinically available genetic tests has expanded rapidly. With many of the technical barriers to 
molecular testing surmounted, the challenge has shifted to improving our interpretation of 
the consequences of genetic variation.
In addition to mutations that cause isolated or familial cardiomyopathy, inborn errors of 
metabolism, neuromuscular diseases and genetic syndromes also cause cardiomyopathy in 
the pediatric population and the differential and diagnostic approach can be complex.(3, 4) 
Because there is practice variation in the approach to genetic diagnosis, there is still much to 
be learned about the genetic basis of pediatric cardiomyopathy. Improved genetic diagnostic 
capabilities promise novel therapeutic approaches and genome editing technologies create 
prospects for the future. In this review, we will discuss the recent novel findings and 
interpretive challenges for genetic testing, highlight some important new genetic discoveries 
across etiologic categories, and present recent progress in utilizing this information for 
management and therapy.
Isolated non-syndromic cardiomyopathy
Mutations in genes encoding sarcomeric proteins are the primary genetic cause of HCM in 
adults and likely the most common cause in children as well.(5) Genetic causes of dilated 
cardiomyopathy (DCM) are identified less frequently, but include genes encoding 
sarcomeric, cytoskeletal, or desmosomal proteins, amongst others. Restrictive 
cardiomyopathy (RCM) and arrhythmogenic ventricular cardiomyopathy (AVC) are rarer 
forms of cardiomyopathy but also are caused by mutations in sarcomeric (RCM) or 
desmosomal (AVC) genes.
Novel gene discoveries for cardiomyopathy often first occur in adults because of increased 
disease prevalence in this age group. The genetic architecture of disease in the pediatric 
population has not been comprehensively studied across all cardiomyopathy phenotypes. Of 
the cardiomyopathy phenotypes, the genetic basis of HCM is the best understood. MYH7 
and MYBPC3 are the most common genes with mutations in isolated HCM and the overall 
diagnostic yield with clinical testing for HCM is high. These two genes appear to account 
for the largest proportion of pediatric cardiomyopathy cases as well.(6) Single center studies 
indicate that the yield of genetic testing may be higher in pediatric HCM patients than in 
adults.(7) Two recent studies have looked at genotype positive, phenotype negative patients 
to determine the penetrance of HCM and find rates of 6–7% during childhood but caution 
that severe hypertrophy and cardiac events can develop.(8, 9) Case reports of multiple 
mutations in pediatric patients with HCM have led to speculation that early onset 
cardiomyopathy may result from “multiple hits”. A recent retrospective review of sarcomere 
mutation carriers showed that 25% of patients < 18 had two or more pathogenic or likely 
pathogenic variants versus 4.8% for adults, but the overall number of pediatric patients 
studied was small (n=24).(10) To date, many studies are limited by their single site status 
and the potential ascertainment bias that occurs at tertiary referral centers. Ascertainment 
bias also exists because genetic assessment and testing of pediatric cardiomyopathy patients 
is rarely standardized and comprehensive. Numbers at single sites are relatively small, and 
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comparison of results between centers is difficult because the populations are not identical. 
A major problem, discussed further below, is that genetic testing interpretation of variant 
pathogenicity has changed due to new evidence provided by large population based 
sequencing datasets.(11, 12) Unless retrospective studies reinterpret “mutation positive” 
patients using updated findings, the likelihood of misclassification is high. Finally, many 
studies do not age stratify the pediatric patients and this may be important in order to define 
whether the genetic etiologies and outcomes are different in infants and preadolescent 
children as compared to adolescent and adult patients.
HCM is classically defined as a disease of the sarcomere. However, in the pediatric 
population, causes are more heterogenous. It is not rare to identify individuals with LAMP2 
(Danon disease) or PRKAG2 (cardiac glycogenosis) mutations that result in early, severe 
hypertrophy. These genetic causes are important to distinguish from sarcomeric mutations 
because of differences in clinical course and prognosis.(13–15) Similarly, individuals with 
Noonan syndrome are sometimes diagnosed with this genetic syndrome years after their 
development of HCM. Because of the increased prevalence of syndromic associations, 
inborn errors of metabolism, mitochondrial disorders, and neuromuscular disease, evaluation 
by a medical geneticist is highly recommended for all types of cardiomyopathy, especially in 
younger children.(4, 16, 17)
The underlying genetic cause of DCM is less frequently identified than for other types of 
cardiomyopathy. Recent data indicate that in the pediatric population there is no survival 
difference between familial DCM and idiopathic DCM after adjustment for other factors.
(18) However, the majority of patients in this study did not undergo genetic testing and 
therefore it is unclear whether there might be a survival difference based on genotype. 
Overall, older age, heart failure, and greater left ventricular dilation at diagnosis were 
independently associated with increased risk of the combined endpoint of transplantation 
and death. Determining whether genotype is predictive of outcome is an important future 
goal.
Mutations in the large cytoskeletal protein titin have emerged as the most common genetic 
cause of DCM in adults and have also been shown to be a risk factor for peripartum 
cardiomyopathy.(19–21) The large size of the TTN gene, encoding titin, creates challenges 
for interpretation of rare variants. Progress has been made in identifying protein domains 
and mutation types that are more likely to be pathogenic if mutated.(20, 22) These findings 
have not been extended to studies in the pediatric population. In analogy to the peripartum 
cardiomyopathy findings, it will be interesting to determine whether rare variants in TTN are 
identified at a higher rate in pediatric patients with concomitant stressors such as 
myocarditis, indicating a genetic susceptibility to the development of disease. Extending 
genetic analyses outside the structural apparatus of the sarcomere, several genes have been 
identified relatively recently that suggest new mechanisms of disease causation. For 
example, mutations in the chaperone protein BAG3 and the splicing factor RBM20 are each 
thought to represent approximately 2% of causes in adult idiopathic DCM. The frequency of 
mutations in these genes in the pediatric population is not known.
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Genetic testing and variant interpretation
Current guidelines recommend genetic testing in children and adults with HCM, and 
consideration of testing in individuals with DCM or RCM.(23–26) Cardiac surveillance is 
recommended for first degree relatives. If genetic testing is positive in the patient, then 
cascade genetic testing of family members is recommended for risk stratification. We 
previously identified that at a single institution, uptake of cardiac surveillance was 
significantly higher than uptake of genetic testing for known familial mutations.(27) 
Khouzam et al. studied factors associated with underutilization of genetic services and 
identified specific health beliefs and awareness important to facilitate care.(28) Genetic 
testing is cost effective as part of the care for families with cardiomyopathy (29) and 
additional investigation of barriers to incorporation of genetic testing into practice is needed.
Genetic testing is probabilistic and results must be interpreted in the context of the patient 
and family history. Choosing the proper genetic testing requires an understanding of the 
genes associated with specific cardiomyopathy phenotypes, variable presentations, 
diagnostic yields of available tests, and the a priori probability of a positive result.(10, 29, 
30) Ideally, a medical geneticist, genetic counselor, or other medical provider well versed in 
cardiovascular genetics and molecular testing should review the interpretation of results. 
Increasing the genetic literacy among cardiovascular genetic care providers is necessary to 
improve the provision of care to this patient population.(31)
In 2015, the American College of Medical Genetics and Genomics and the Association for 
Molecular Pathology released standards for the interpretation of genetic variants identified 
by clinical testing.(32) These standards delineate 5 potential interpretations for molecular 
testing results (Table 1) and are intended to improve the consistency of variant interpretation. 
Interpretation of variants is a rapidly evolving as widespread sequencing efforts and public 
databases such as the Exome Aggregation Consortium (http://exac.broadinstitute.org), and 
the 1000 Genomes Project Exome Sequencing Project (http://evs.gs.washington.edu/EVS) 
lend insight into the frequency of rare variants in the population and allow comparison to 
cardiomyopathy cohorts.(11, 12, 33, 34) These studies have highlighted that rare genetic 
variation is, in aggregate, much more common than anticipated and is present to a 
substantial degree within healthy individuals. There has been a significant effort to reassess 
past interpretation of genetic variation in cardiomyopathy patients. In some cases, this has 
led to revision of previous clinical genetic test reports and serves as a reminder that it is 
imperative to assess testing results in the context of the dynamic family history and to update 
interpretations frequently. ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) is an important 
resource for reporting human genetic variation and phenotypes. It allows the deposition of 
supporting evidence and assertion criteria that aid in the communication about interpretation 
of human variation and health status. ClinGen (https://www.ncbi.nlm.nih.gov/clinvar/docs/
clingen/) reviews data about genotype-phenotype relationships from ClinVar and additional 
sources and generates a report, including medical actionability. These resources represent 
important efforts to share genetic and clinical information to inform variant interpretation.
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Integrative genomics: the transcriptome in pediatric cardiomyopathy
In addition to novel discoveries at the gene level, there have been important new discoveries 
resulting from the assessment of the transcriptome in patients with cardiomyopathy. DCM 
and heart failure in adults is molecularly characterized by transcriptional alterations in 
metabolic networks; in addition, there are distinct mRNA splicing patterns, including 
activation of embryonic splicing patterns and alterations in RBM20-mediated splicing in 
diseased hearts.(35–39) Far less is known about the transcriptome in pediatric hearts. While 
animal models indicate that fetal and neonatal gene expression differs from adult hearts, the 
temporal shifts in transcriptional profiles have not been well characterized in pediatric 
patients. Several recent studies investigate the molecular findings in explanted hearts from 
children with heart failure and demonstrate age-related differences. Pediatric patients with 
DCM showed a differential adaptation of the β-adrenergic signaling pathway when 
compared to adults with DCM or non-failing controls.(40) Specifically, down-regulation of 
β1- and β2-adrenergic receptors is identified in children, whereas β2-AR expression is 
maintained in adults. Differences in the phosphorylation status of phospholamban are also 
noted in children versus adults.(40) Phosphodiesterase isoform expression and 
responsiveness to phosphodiesterase inhibition also differed in pediatric versus adult 
samples.(41, 42) Defining normal transcriptional profiles during infancy and other pediatric 
age ranges is important to better understand how to optimize treatment approaches.
In addition to these investigations in DCM patients, RNA-Seq was recently performed on a 
cohort of pediatric RCM patients and compared to other forms of adult cardiomyopathy and 
controls.(43) This identified molecular pathway dysregulation that was common to the 
cardiomyopathies, as well as those unique to RCM. Transcripts selectively induced in RCM 
include many known and novel G-protein coupled receptors linked to calcium handling and 
contractile regulation. In-depth comparisons of alternative splicing implicate RBM20 as a 
potential mediator of alternative splicing in RCM. Interestingly, the disruption of alternative 
splicing patterns in pediatric RCM occurs in the inverse direction as in adult DCM. Taken 
together, these initial investigations of the pediatric cardiomyopathy transcriptome indicate 
that while there are molecular signatures that overlap with adult cardiomyopathy, phenotype- 
and age-specific profiles exist that can provide useful mechanistic data for possible 
intervention.
Epigenetics and pediatric cardiomyopathy
MicroRNAs (miRNAs), noncoding RNAs that consist of 18 to 22 nucleotides, are important 
regulators of gene expression at the post-transcriptional level and act as important 
modulators of cardiac hypertrophy, heart failure, and fibrosis.(44) Study of miRNAs in 
mouse models has shown that overexpression can result in cardiac hypertrophy and heart 
failure and that deletion can be protective. Upregulation of specific miRNAs can also be 
seen in patients with heart failure.(45) For these reasons, combined with the fact that 
miRNAs are relatively stable in the blood, miRNAs have generated interest as circulating 
biomarkers for use in clinical care. To date, miRNAs have not been well studied in pediatric 
cardiomyopathy patients, but an early study indicates that children with heart failure have 
unique miRNA profiles.(46) Long noncoding RNAs (lncRNAs) are another group of RNA 
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molecules that play important roles in development and disease through their function in the 
regulation of transcriptional and post-transcriptional events. For example, the mitochondrial 
lncRNA LIPCAR identified patients undergoing cardiac remodeling who were 
independently at risk for future cardiovascular deaths.(47) Identifying miRNAs and 
lncRNAs that are important in the pediatric population and understanding developmental-
specific regulation may provide additional insight into epigenetic mechanisms in pediatric 
cardiomyopathy.
Toward novel disease-specific therapeutics
Precision medicine is increasingly viewed as a means to establish individualized 
management and therapeutic plans that will lead to improved outcomes. In pediatric 
cardiomyopathy a first step toward precision medicine is understanding the underlying cause 
of the patient’s disease. Recent progress in disease specific therapeutics has produces some 
exciting results. For example, infants with Pompe disease are now treated with enzyme 
replacement therapy (ERT) in order to ameliorate HCM. Early diagnosis is critical in order 
to optimize outcomes.(48) There is recent evidence that the development of HCM is not 
limited to the classic infantile-onset disease and that Pompe disease represents a continuum.
(49) An interesting recent report also showed the use of ERT for storage caused by a 
PRKAG2 mutation.(50)
Whereas treatment of HCM in Pompe disease uses replacement of the deficient enzyme, 
new therapy in Noonan syndrome and Noonan syndrome with multiple lentigenes (NSML, 
formerly LEOPARD syndrome) is directed at correcting the dysregulation of RAS-MAPK 
signaling. Mutations in PTPN11 are the most common cause of Noonan syndrome, where 
they result in constitutive activation of the protein. New genes causing Noonan syndrome 
and related RASopathies continue to be identified (Table 2). In contrast, in NSML mutations 
in PTPN11 render the protein catalytically impaired. Greater than 80% of patients with 
NSML have HCM that is caused by hyperactivation of the AKT/mTOR pathway. Thus 
mutations in the same gene can both cause HCM but via different mechanisms. This has 
important therapeutic implications. The ability to prevent HCM was investigated in a mouse 
model of NSML by early treatment with the mTOR inhibitor rapamycin. Mice treated early 
did not develop HCM, and those treated at later stages demonstrated reversal of disease.(53) 
Recently, the first trial of a mTOR inhibitor was reported in an infant with NSML and 
rapidly progressive HCM. Therapy was initiated with a goal of halting progression of 
hypertrophy and outflow tract obstruction until transplant.(54) Pathway specific inhibitors 
allow therapeutics to be tailored to the underlying genetic cause of disease.
Antagomirs, molecules used to inhibit miRNAs, have shown promise in animal models for 
inhibiting the development and progression of cardiomyopathy. For example, blocking 
profibrotic miRNAs with antagomirs in a mouse model of HCM resulted in decreased 
interstitial fibrosis and increased cardiac function. The development of antagomirs for 
therapeutic use in heart failure is reportedly in preclinical development.(55)
Finally, the ability to perform genome editing has generated substantial enthusiasm about the 
ability to “correct” mutations and restore normal function. When paired with research using 
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human induced pluripotent stem cells (iPSC), these new technologies provide opportunities 
to understand the consequence of a pathogenic variant in the context of the patient’s 
individual genetic variation. For example, recent studies of TAZ variants causing Barth 
syndrome using gene replacement and genome editing in iPSC demonstrated the necessity 
and sufficiency of the variants for phenotypes including sarcomere assembly and myocardial 
contraction abnormalities.(56) Human engineered cardiac tissues from a patient with a 
BRAF mutation recapitulated the HCM phenotype, providing a cell culture approach to 
study disease mechanisms and therapies in vitro.(57) Genome editing capabilities have also 
generated specific interest as a mechanism to correct a mutant allele encoding a structural 
component of the sarcomere in isolated non-syndromic cardiomyopathy. In a mouse model 
of HCM, adenoviral constructs were used to silence the mutant allele but not the wild-type 
allele, ameliorating the disease phenotype.(58) In another study using iPSCs, a mutation in 
phospholamban was shown to impair cardiomyocyte contractility and targeted genetic 
correction of the mutation rescued this defect.(59) These studies illustrate the power of 
combining iPSC and genome editing to understand the functional significance of genetic 
variation.
Conclusion
Cardiomyopathy is not a single disease but multiple diseases with different underlying 
causes. Understanding the genetic basis of disease is a critical first step to design patient-
specific management and therapy. Improving our ability to interpret genetic variation is 
necessary to properly assign causality. Ongoing investigation of the transcriptome and 
epigenome in pediatric patients will provide novel information about disease progression 
and outcome and may provide novel targets for therapeutic intervention. Genome editing 
and induced pluripotent stem cells provide novel tools to investigate genetic variation. 
Several disease-specific or gene-specific approaches have emerged and have promising 
results.
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Key points
• Pediatric cardiomyopathy is genetically heterogeneous and may be isolated or 
occur as part of a syndrome, neuromuscular disorder or metabolic disease.
• Enhanced sequencing capabilities allow rapid identification of novel 
candidate genes or alleles causing cardiomyopathy; proof of causality is more 
challenging.
• In aggregate, rare genetic variation is relatively common in the population. 
Understanding the scope of genetic variation in healthy individuals has 
allowed refinement and increased stringency of interpretation of variant 
pathogenicity.
• Transcriptome and epigenome analyses are contributing new information to 
our understanding of pediatric cardiomyopathy and its similarities to and 
differences from adult cardiomyopathy.
• Management and therapy directed to the underlying genetic cause of 
cardiomyopathy is becoming available and highlights the promise of precision 
medicine.
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Table 1
Variant classification Criteria
Pathogenic Predicted null variant in gene where loss of function is known disease mechanism; de novo variant; absent in 
population databases or MAF very low; co-segregation in multiple families; computational predictions 
support deleterious effect; functional data support deleterious effect
Likely Pathogenic Criteria similar to pathogenic but with less supporting evidence such as fewer available families for co-
segregation data, contradictory computational predictions or weaker functional data
Variant Uncertain Significance Very low population frequency or absent from databases but lacking co-segregation, computational, and/or 
functional evidence for pathogenicity
Likely Benign Allele frequency greater than expected for disease incidence; allele identified in young, healthy individuals; 
no effect in functional assays; lack of segregation in family members; and/or mutation type not consistent 
with known disease mechanism
Benign MAF >5% in ExAC or ESP OR 2 or more of the likely benign criteria
ESP, Exome Sequencing Project; ExAC, Exome Aggregation Consortium; MAF, minor allele frequency. For detailed criteria, see Richards et al. 
(32)
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Table 2
Noonan syndrome and other RASopathies
Gene % of Patients Comments
PTPN11 50% Also causes NSML
SOS1 10–15% High prevalence of ectodermal abnormalities
RAF1 5% HCM in > 80%; also causes NSML
RIT1 5% High incidence of congenital heart disease; HCM in 70%
KRAS 2% Also associated with CFC syndrome
BRAF 1–2% Usually seen in CFC syndrome
NRAS <1%
A2ML1 unknown candidate
LZTR1 unknown candidate
RASA2 unknown candidate
SOS2 unknown candidate; ectodermal defects
RRAS candidate; Noonan like syndrome
HRAS Costello syndrome; activating mutations
MAP2K1 2% CFC syndrome
MAP2K2 CFC syndrome
SHOC2 2% Noonan-like syndrome
CBL Noonan-like syndrome
CFC, Cardiofaciocutaneous syndrome; NSML, Noonan syndrome with multiple lentigenes; Table compiled from (51, 52) and GeneReviews.
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